ActivePure Medical Joins Forces with Lighthouse Environmental Infection Prevention

ActivePure Medical LLC, the healthcare division of ActivePure Technologies LLC, announced today that Lighthouse Environmental Infection Prevention, the worldwide leader in environmental infection prevention and control, will represent the company as its acute care customer acquisition team in the United States.

Lighthouse is led by John LaRochelle, a former executive at Sodexo where he managed their global cleaning and disinfecting portfolio. Lighthouse’s team of infection prevention advisors has decades of experience finding, developing and implementing innovative solutions to reduce infection rates in healthcare systems. Lighthouse excels at developing custom solutions that improve the environment of care and they currently service more than 500 hospitals nationwide.

Lighthouse has partnered with ActivePure Medical, formerly Aerus Medical, to add continuous disinfection technology to their portfolio to address the contamination that occurs in between the routine cleaning and disinfection. ActivePure offers a range of continuous, full-facility surface and air disinfection products specifically designed for healthcare settings.

“We are excited to partner with ActivePure Medical.  Their best-in-class ActivePure Technology is an important addition to our portfolio of technologies, services, environmental testing and consulting services to stop the transmission of pathogens in healthcare facilities and reduce HAIs.  ActivePure’s FDA cleared class II medical devices, extensive clinical testing showing effectiveness, range of products and expertise assures we can create a solution for most healthcare facilities,” states Doug Manchester, Managing Partner of Lighthouse Environmental Infection Prevention.

ActivePure Medical and Lighthouse will position ozone-free, CARB certified ActivePure Guardian products made in EPA-registered establishment number 87327-VA-1 under ActivePure Manufacturing, LLC, in the hospital market. The industry-leading ActivePure Medical Guardian, an FDA cleared Class II Medical Device which received 510k status in 2020, will be among the products available.

“This opportunity provides Lighthouse improved access to our gold-standard continuous surface and air disinfection products and will enhance their comprehensive environmental infection prevention programs. ActivePure is the only brand that offers automated, proactive, and full-facility continuous surface and air disinfection that minimize pathogens and contaminants in the air and on surfaces in real-time and in areas occupied by patients and staff,” said Dan Marsh, president of ActivePure Medical. “Acute care facilities are an important channel for us, and we are very passionate about helping them in their efforts to achieve zero healthcare-associated infections (HAIs).”

All ActivePure Guardian products are designed to be effective against the most resistant pathogens found in the healthcare environment, such as MRSA, VRE, and c. Difficile spores. The ActivePure Technology has been independently tested against a broad spectrum of clinically relevant surface and airborne pathogens, including H1N1, SARS-CoV-2, Aspergillus Niger, and more. Testing can be found on file at ActivePureMedical.com. ActivePure Medical Guardian is currently undergoing a two-year, double-blind study at the Cleveland Clinic to measure effectiveness against Surgical Site Infections (SSIs). ActivePure has other real-environment case studies, including in healthcare spaces showing significant reductions in bacteria, viruses, and incidences of MRSA.

ActivePure Medical products are safe to use in spaces occupied by people, making the suite of continuous surface and air disinfection products an ideal solution for facility-wide adoption in the healthcare space. These safe and highly effective products come in both heating, ventilation and air conditioning (HVAC) induction variations and plug-and-play, installation-free portable units. The types of ActivePure Guardian units configured for medical facilities depend largely on the facility’s HVAC plans, layout, and independent needs or risks; most facilities use a combination of portable and induct units. To ensure that every healthcare facility has the ideal solution, ActivePure Medical’s team of experts will consult and review each facility’s specific infection prevention needs and propose a customized solution for the space.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version